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ABSTRAK
Acquired hemophilia A (AHA) adalah sebuah kelainan pembekuan darah yang disebabkan adanya 
autoantibodi (inhibitor) terhadap faktor VIII. Gejala yang khas adalah perdarahan bawah kulit dan jaringan 
lunak (jarang pada sendi), tanpa ada riwayat keluarga maupun riwayat perdarahan sebelumnya. Wanita, 39 
tahun, lebam di kedua lengan bawah hilang timbul selama 2 bulan tanpa riwayat trauma. Riwayat konsumsi obat 
nyeri kepala sejak SMP. Pemeriksaan faal hemostasis didapatkan pemanjangan activated partial tromboplastin 
test (APTT) 87,1 (24,4-44,4detik) dan rendahnya kadar faktor VIII 5%(60-150%). Pemberian rekombinan 
faktor VIII membuat kadar faktor VIII menjadi semakin turun (2%). Titer inhibitor faktor VIII 21,12 Bethesda 
unit sehingga pasien didiagnosis AHA. Penyebab AHA pada penderita ini kemungkinan adalah penggunaan 
non-steroid anti-inflammatory drug (NSAID) jangka lama. Kasus ini merupakan kasus yang masih jarang 
ditemukan di Indonesia sehingga tata cara diagnosis dan terapinya masih kurang. Terapi yang tidak tepat dapat 
menyebabkan kadar faktor VIII semakin menurun.
Kata kunci: acquired hemophilia, non-steroid anti-inflammatory drug (NSAID), inhibitor, faktor VIII.
ABSTRACT
Acquired hemophilia A (AHA) is a blood clotting disorder caused by the presence of autoantibodies 
(inhibitors) against factor VIII. The typical symptom of this disorder is bleeding under the skin and soft tissue 
(rarely in the joints), with no family or personal previous history of bleeding. This case reports is tended to build 
up awareness for better diagnosis and therapy. Woman, 39 years old, bruises on both forearms are intermittent 
for 2 months with a history of long term drug consumption for headache treatment. Hemostatic test showed the 
elongation of activated partial thromboplastin test (APTT) to 87.1 (normal 24.4-44.4 seconds) and the decreament 
of factor VIII (FVIII) activity to 5% (normal 60-150%). Provision of recombinant factor VIII lowered factor VIII 
activity to 2%. Factor VIII inhibitor titer was 21.12 BU and diagnosis AHA was made. Inhibitor eradication 
by methylprednisolone tablet 3x16mg which was given for 2 months, improved the APPT to 46.7 seconds and 
factor VIII activity to 36%. Acquired Hemophilia A should be suspected in an adult bleeding patient with history 
of taking a long time non-steroidal anti-inflammatory drugs (NSAIDs). This case is a rare case in Indonesia 
and therefore the procedure for diagnosis needs to be improved in order to avoid errors in delivering a therapy 
which can cause the decreament of factor VIII activity.
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INTRODUCTION
Acquired hemophilia A (AHA) is a blood 
clotting disorder caused by the presence of 
autoantibodies that interfere with the function of 
factor VIII, or often called factor VIII inhibitor.1 
This disorder is less common than congenital 
hemophilia, but it is more life threatening. Its 
prevalence is similar in men and women i.e. 
0.28 /million/year at age <65 years old, rising 
to 5.97/million/year for 65-85 years old, up to 
16.6/million/year for those aged> 85 years old.2 
Acquired hemophilia A is usually associated 
with autoimmune diseases, malignancies, skin 
disorders, drug interactions, and the period after 
childbirth; even 50% of cases has unknown 
causes (idiopathic).3-5
Acquired hemophi l ia  A was of ten 
misdiagnosed as another blood clotting disorder. 
Its bleeding manifestation was different from 
the congenital hemophilia. The bleeding often 
occurs under the skin (purpura/ecchymosis) 
and soft tissue, and rarely found in the joints 
(hemarthroses).2,6 The presence of factor VIII 
inhibitor causes a disruption in the intrinsic 
coagulation pathway, causing elongation of the 
activated partial thromboplastin time (APTT) 
parameter which did not show improvement after 
mixing test and it has low activity of factor VIII.3
Management of patients with AHA aims to 
overcome the bleeding and its complications, 
as well as the eradication of the factor VIII 
inhibitors. Eradication of the inhibitor with 
immunosuppressive therapy usually begins with 
corticosteroids such as prednisolone 1 mg/kg/
day. The treatment is continued for 3 months, 
while patient’s response to therapy is being 
monitored.6-8
This case report is intended to build up 
awareness for better diagnosis and therapy. This 
article highlights a case of an adult woman, with 
a history of long term NSAIDs consumption for 
headache treatment, that experience a history of 
spontaneous bleeding under the skin for one and 
a half months. She finally was being diagnosed 
with AHA.
CASE ILLUSTRATION
A 39-year-old woman went to the doctor on 
December 2015 with complaints of intermittently 
spontaneous bruises on both arms since the 
beginning of November 2015, with no tenderness 
found on the bruises. A history of trauma was 
denied by the patient. She also reported minor 
bleeding gums when she brushed her teeth. 
There were no bruises on the joints and a history 
of nosebleeds or unstoppable bleeding due to 
injuries was denied. The menstrual cycle of the 
patient was normal and the drastic weight loss 
in recent months was denied as well.
The patient had a history of regular frequent 
intake of a drug which contains acetosal, 
paracetamol, and caffeine, for headache treatment 
since she was in junior high school. She had 
consulted several times with a neurologist and 
then was diagnosed as migraine. A few years 
ago, she had a head CT Scanning with normal 
result. The patient is the first child of 3 siblings 
and married with two children who were born 
normally with no history of bleeding prior to, 
during, and after childbirth. The youngest child 
of the patient is 10 years old.
The patient’s general state looked healthy, 
weight 52 kg, with the vital signs of blood 
pressure 120/70 mm Hg, pulse rate 84 beats/min, 
respiratory rate 20 times/min, and temperature of 
370C. Head and neck had a little anemia, without 
jaundice, cyanosis, and dyspnea. The thoracic 
examination indicated symmetrical movements, 
no retraction, normal sound of heart and lungs. 
Abdomen examination was found flexible, 
and also normal bowel sound, liver and spleen 
were not palpable. The extremities examination 
were found warm, dry, red, but in the region 
of the right and left forearms, were obtained 
fairly extensive ecchymosis without tenderness 
(Figure 1).
All laboratory result was shown the initial 
CBC; normochromic anemia, increament 
number of platelet, and elongation of APTT with 
normal plasma prothrombine time (PPT). Liver 
and kidney function test results were within 
normal limits and anti-nuclear antibody (ANA) 
was not detected. The patient was referred to a 
hematologist and medical oncologist consultant 
who gave her a referral to conduct laboratory 
examinations. The test results showed very 
low activity of factor VIII with normal von 
Willlebrand factor and fibrinogen level. The 
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patient was hospitalized on December 22nd, 2015 
for three days and was treated with recombinant 
factor VIII 1500 IU/day. The next examination 
(December 28th, 2015) showed that factor VIII 
activity decreased after recombinant factor VIII 
therapy despite the diminishing symptoms of 
ecchymosis (Figure 2).
Figure 1. Ecchymosis on left forearm.
Figure 2. Ecchymosis on left forearm after recombinant 
factor VIII therapy.
Examination of factor VIII, factor IX activity 
and inhibitor of factor VIII done in January 4th, 
2016 revealed that factor VIII activity was low, 
whereas factor IX activity was normal. The 
examination of factor VIII inhibitor level using 
the Bethesda titer showed a high level at 21.12 
BU (Bethesda Units). Examination of circulating 
anticoagulant—which is a modification method 
from Bethesda titer—showed that the inhibitor 
concentration is still high despite the patient’s 
factor VIII activity has increased. One part of the 
patient plasma which was mixed with nine parts 
of control plasma, have not produced normal 
APTT value yet.
Therapy of methylprednisolone 3x16 mg/
day for two weeks could diminish the inhibitor 
of factor VIII. Examination after two weeks 
of therapy showed an increase in factor VIII 
activity; the methylprednisolone was being 
tappered-off until third month of therapy. Factor 
VIII activity was increasing at the end of the 
second month of treatment. The inhibitor was 
not detected in the end of therapy.
DISCUSSION
Hemophilia A is a bleeding disorder caused 
by disturbances in factor VIII. This disorder can 
be present at birth (congenital) due to mutations 
in genes forming factor VIII or may appear in 
adulthood (acquired). Gene mutation which 
shapes congenital factor VIII in hemophilia 
is inherited because it is linked to the X 
chromosome (X-linked inherited), so that this 
disorder is mostly suffered by men.1,7 Acquired 
Hemophilia A (AHA) is a rare case in which 
the body produces autoantibodies (usually IgG) 
against factor VIII.8 The disorder is not inherited 
so that men and women have similar prevalence 
to suffer AHA.1,9,10
Factor VIII activity in patients with AHA 
is not comparable with the arise symptoms of 
bleeding, unlike congenital hemophilia patients 
who show the severity of bleeding related to 
the activity of factor VIII.2,6 This case showed 
an adult female patient who was eventually 
diagnosed with AHA. AHA diagnosis in this 
patient was based on her clinical symptoms of 
bleeding under the skin which emerge when 
the patient has grown up as an adult, with no 
previous personal history of bleeding or a 
history of bleeding in the family. Anemia that 
was shown from decreased levels of hemoglobin 
and hematocrit of the patient showed that the 
bleeding happens quite a lot. The differential 
diagnosis of this patient was another blood 
clotting factor deficiency, lupus anticoagulant, 
and von Willebrand disease (vWD). The activity 
of factor IX and von Willebrand factor showed 
normal results, while symptoms of lupus 
anticoagulant led to thrombosis rather than 
haemorrhage.
Causes of AHA 50% is unknown (idiopathic), 
20% are due to an autoimmune disease, 10% as 
a result of pregnancy, while the rest is due to 
malignancy or interactions with drugs such as 
antibiotics, non-steroidal anti-inflammatory 
drugs (NSAIDs) and aspirin, anticonvulsant, or 
anti hypertension.9,10 The clinical symptoms of 
the patient did not show any autoimmune disease, 
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supported by negative ANA result; so that the 
cause of AHA in this patient may be caused by 
anti-drug interaction or idiopathic headache. 
Patient was also not in a pregnant condition or 
had just given birth so that the possible cause 
of AHA is the long term consumption of anti-
headache drug (NSAID).
The elongation of APTT value and low 
activity of factor VIII showed that the patient 
experienced hemophilia A. The cause of APTT 
elongation should be determined by conducting 
a mixing test in advance, i.e. 1 part of patient 
plasma is mixed with 1 part of normal plasma, 
and then the value of its APTT is subsequently 
re-measured.9 The result of APTT after mixing 
test which was not corrected is 50% (24/3/16: 
Mixing test 1:1 APTT=39.6 seconds); it indicates 
that the value of APTT elongation caused by the 
inhibitor is not due to deficiency of factor VIII.
Factor VIII inhibitor was confirmed by 
checking the levels of inhibitor using the 
Bethesda method. The inhibitors in patients 
with AHA is an autoantibody that is dependent 
on time and temperature, so that incubation of 
patient plasma with normal plasma was done for 
2 hours at 37°C.7,9,10 The examination produced a 
high titer inhibitor (21.12 BU). Type 1 inhibitor 
(first-order kinetics) can usually be formed in 
20-40% of patients with congenital hemophilia A 
as a result of treatment with recombinant factor 
VIII (aloantibody); whereas inhibitor in patients 
with AHA is a type 2 inhibitor. Type 1 inhibitor 
showed the complete inactivation of factor 
VIII in accordance with the time of incubation, 
whereas type 2 inhibitor showed inactivation 
of factor VIII that formed the plateau graph 
(Figure 3).7
At a glance, this experiment figures are 
similar to those of APTT examination of the 
patient’s blood samples. The patient’s APTT 
value at initial examination was 46.1 seconds. 
A mixing test with normal plasma in the “hour 
0” (t=0) generated APTT value of 27.9 seconds. 
APTT value after one hour incubation with 
normal plasma was 30.3 seconds, after two hours 
incubation with normal plasma was 36.5 seconds, 
and after three hours incubation, the APTT value 
was 36.5 seconds (Figure 4). Figures of inhibitor 
types were visible at the second and third hour 
of examination.
The principle of AHA patient therapy is 
aimed at stopping bleeding and eradicating 
the inhibitors. Provision of recombinant factor 
VIII is not recommended in patients with 
factor VIII inhibitor levels >5 BU (Bethesda 
Units), as it would further increase its inhibitor 
level.7,12,13 Bypassing agent therapy such as active 
recombinant factor VII has shown good results 
in stopping the bleeding; while to eradicate 
inhibitors, it commonly uses immunosuppressive 
drugs such as corticosteroids, cytotoxic agents 
(cyclophosphamide, cyclosporine), and 
rituximab (monoclonal antibody anti CD-
20).2,9,11 Monitoring of therapy can be done by 
checking factor VIII activity and factor VIII 
inhibitor which are done regularly (after 7-8 
weeks of therapy).9,14,15 Patients in this case 
showed a good response to oral corticosteroids 
(methylprednisolone) with a single dose of 1 
mg/kg/day. Factor VIII activity at the end of 
Figure 3. Activity of type 1 and type 2 inhibitor on factor VIII 7
Figure 4. The APTT graph with incubation time of patient 
plasma:normal plasma (1:1).
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the second month of therapy increased to 36%. 
Methylprednisolone dose was then lowered 
gradually and the drug was stopped on the third 
month of therapy. Inhibitor was undetectable and 
the examination of factor VIII activity showed 
43% (normal) at the end of the fifth month.
CONCLUSION
Acquired Hemophilia A is rare so that the 
procedures for the diagnosis and treatment are 
still very limited. The patient was diagnosed 
with AHA because bleeding symptoms under the 
skin appeared in adult age with no prior history 
of bleeding. Test results show an elongation of 
APTT value, low activity of factor VIII, and 
high level of factor VIII inhibitor. The possible 
cause of AHA in this patient is the long term 
consumption of NSAIDs. Single steroid therapy 
per oral and discontinuation of NSAIDs was 
found to eradicate the inhibitor of factor VIII 
in the patient’s body. The procedure for AHA 
diagnosis needs to be improved in order to avoid 
errors in delivering a therapy which can cause 
the decreament of factor VIII activity.
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